Copertina

Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R‐ISS II patients

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Maria Papatsirou, Christos K. Kontos, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Diamantis C. Sideris, Despina Fotiou, Christine‐Ivy Liacos, Maria Gavriatopoulou, Efstathios Kastritis, Meletios A. Dimopoulos, Andreas Scorilas, Evangelos Terpos
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	HemaSphere
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Single‐cell analysis of MYD88L265P and MYD88WT Waldenström macroglobulinemia patients
di: Tina Bagratuni, et al.
Pubblicazione: (2024)

Central nervous system myeloma: Pathogenesis, diagnostic challenges, and practical management strategies
di: Eirini Katodritou, et al.
Pubblicazione: (2025)

Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
di: Niels W. C. J. van de Donk, et al.
Pubblicazione: (2025)

Evaluation of the R2‐ISS in real‐world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202)
di: Hyungwoo Cho, et al.
Pubblicazione: (2024)

Daratumumab‐based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study
di: Meral Beksac, et al.
Pubblicazione: (2026)

Navigating the evolving management of smoldering multiple myeloma
di: M. Bakri Hammami, et al.
Pubblicazione: (2026)

European Myeloma Network Group Consensus Statement on the use of next‐generation sequencing for prognostic stratification of newly diagnosed multiple myeloma
di: Niccolò Bolli, et al.
Pubblicazione: (2025)

High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience
di: Veronica González‐Calle, et al.
Pubblicazione: (2024)

Expression profile of Bcl‐2 family proteins in newly diagnosed multiple myeloma patients
di: Cristina De Ramón, et al.
Pubblicazione: (2024)

Interferon gamma‐mediated prevention of tumor progression in a mouse model of multiple myeloma
di: Zoltán Kellermayer, et al.
Pubblicazione: (2024)

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes
di: Kazimierz Groen, et al.
Pubblicazione: (2024)

Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma
di: Patrick Born, et al.
Pubblicazione: (2025)

Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma
di: Larissa Haertle, et al.
Pubblicazione: (2024)

Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma
di: Juan‐Jose Garces, et al.
Pubblicazione: (2025)

CDK6 protein expression is associated with disease progression and treatment resistance in multiple myeloma
di: Johannes Steinhart, et al.
Pubblicazione: (2024)

Combining SKY92 gene expression profiling and FISH (according to R2‐ISS) defines ultra‐high‐risk Multiple Myeloma
di: Xiang Zhou, et al.
Pubblicazione: (2025)

Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma
di: Ola Landgren, et al.
Pubblicazione: (2025)

Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53‐deficient myeloma cells
di: Romane Durand, et al.
Pubblicazione: (2024)

Preclinical evaluation of the CD38‐targeting engineered toxin body MT‐0169 against multiple myeloma
di: Wassilis S. C. Bruins, et al.
Pubblicazione: (2024)

The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma
di: Anna de Daniel, et al.
Pubblicazione: (2024)

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet‐treated multiple myeloma without transplant
di: Benjamin A. Derman, et al.
Pubblicazione: (2025)

High‐risk features of early relapse in newly‐diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy
di: Andrea Manubens, et al.
Pubblicazione: (2025)

Correction to “Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network”
Pubblicazione: (2025)

Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study
di: Sonia Morè, et al.
Pubblicazione: (2025)

Impact of second autologous stem‐cell transplantation at relapsed multiple myeloma: A French multicentric real‐life study
di: Axel André, et al.
Pubblicazione: (2024)

30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis
di: Enrique M. Ocio, et al.
Pubblicazione: (2024)

Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant
di: Prashant R. Tembhare, et al.
Pubblicazione: (2024)

Monocyte‐mediated metabolic rewiring via CD31‐CD38 interactions promotes growth and drug‐resistance in multiple myeloma
di: Ramin Raoof, et al.
Pubblicazione: (2026)

Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study
di: Michael H. Tomasson, et al.
Pubblicazione: (2024)

Correction to Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study
Pubblicazione: (2025)

Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single‐cell profiling in anti‐BCMA CAR T‐treated myeloma
di: Thomas C. Wiemers, et al.
Pubblicazione: (2026)

Uncovering the ultra‐frail: A distinct subgroup in non‐transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome
di: Kazimierz Groen, et al.
Pubblicazione: (2025)

Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first‐line therapy irrespective of frailty levels
di: Wassilis S. C. Bruins, et al.
Pubblicazione: (2025)

Mortality in patients with lymphoid malignancies and multiple myeloma was stable upon and during the COVID‐19 pandemic: A population‐based, nation‐wide study
di: Tereza Faitová, et al.
Pubblicazione: (2024)

Bortezomib before and after high‐dose therapy in transplant‐eligible patients with newly diagnosed multiple myeloma: Long‐term overall survival after more than 10 years of follow‐up from the phase III HOVON‐65/GMMG‐HD4 trial
di: Elias K. Mai, et al.
Pubblicazione: (2024)

Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab era
di: Abdul‐Hamid Bazarbachi, et al.
Pubblicazione: (2025)

MMS22L is a novel key actor of normal and pathological erythropoiesis
di: Elia Colin, et al.
Pubblicazione: (2025)

Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium
di: Cristina A. Tentori, et al.
Pubblicazione: (2024)

Issue Information
Pubblicazione: (2025)

Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia
di: Raúl Córdoba, et al.
Pubblicazione: (2026)